Clinical trial NCT01501604: BKM120 in Cancers With PIK3CA Activating Mutations
Official title: An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Lung Cancer
Breast Cancer
Colorectal Cancer
Cholangiocarcinoma
Solid Tumors
Keywords: PIK3CA mutation
Advanced solid tumors
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2011-12-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In people whos cancers have a PIK3CA mutation, this trial will be evaluating the drug BKM120 as a possible treatment. BKM120 works by blocking the phosphatidylinositol-3-kinase (PI3K)pathway, thereby inhibiting tumor growth and survival.

The purpose of this study is to learn if the study drug BKM120 can shrink or slow the growth of your tumor. The safety of BKM120 will also be studied. Your physical state, symptoms, change in the size of your tumor, and laboratory findings obtained while you are on study will help the research team decide if BKM120 is safe and effective in patients with advanced cancers.

Detailed description: Subjects enrolled in this study will receive BKM120 once daily, orally, in cycles of 28 days.

During Cycles 1 and 2, the following tests and procedures will be done on days 1 and 15:

* physical exam
* performance status
* blood tests
* pregnancy test (if applicable)
* neuropsychiatric assessments

Starting at Cycle 2 and then every other cycle thereafter (approximately every 8 weeks) tumor assessment will be performed by CT/MRI or PET scan. A chest x-ray will also be performed every 8 weeks.

Beginning with Cycle 3, the following tests/procedures will be performed on Day 1 of each cycle:

* physical exam
* performance status
* blood tests
* neuropsychiatric assessments

Eligibility criteria: Inclusion Criteria:

* At least 1 site of measurable disease
* Life expectancy \>/= 12 weeks
* Adequate marrow and organ function
* Diagnosis of lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma, gastric cancer, pancreatic cancer, prostate cancer, uterine cancer, ovarian cancer, esophageal cancer, or head and neck cancer
* Pathologically documented, definitively diagnosed, advanced solid tuor that is refractory to standard treatment, for which no standard therapy is available, or the subject refuses standard therapy
* Cancer must have at least one of the following PIK3CA mutations: E542K, E545K, H1047R, H1047L. The PIK3CA mutation must be documented in a CLIA approved laboratory

Exclusion Criteria:

* Prior treatment with a P13K inhibitor
* Known hypersensitivity to BKM120 or its excipients
* Untreated brain metastases
* Acute or chronic liver, renal disease or pancreatitis
* Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A
* Diarrhea \>/= CTCAE grade 2
* Any concurrent severe and/or uncontrolled medical condition
* Active cardiac disease
* History of cardiac dysfunction
* Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus
* Significant symptomatic deterioration of lung function
* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKDM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
* Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant
* Pregnant or breast-feeding
* Known diagnosis of HIV infection
* History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
* Unable to swallow the medication in its prescribed form

Primary outcomes:
measure: Response Rate
timeFrame: 2 years
Secondary outcomes:
measure: Clinical Benefit Rate
timeFrame: 2 years
measure: Survival
timeFrame: 2 years
measure: Clinical Benefit
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Massachusetts General Hospital
name: Jeffrey A Engelman, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: